menu

ReachMD

Be part of the knowledge.
Register

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

Highlights from the 13th International Congress of the Society for Melanoma Research: A Focus on Checkpoint Inhibition

Updates on the use of immunotherapy in melanoma as presented at this year’s Society for Melanoma Research Congress

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Immunotherapy, notably overcoming checkpoint inhibition, has become an integral part of treatment for melanoma, if not a growing list of other cancers.  In this activity, Dr. Michael Postow discusses major updates on the use of immunotherapy in melanoma as presented at the 13th International Congress of the Society for Melanoma Research that took place recently in Boston, Massachusetts. Topics include the general mechanistic principles behind immune checkpoint blockade in the treatment of metastatic melanoma; the current landscape of immune checkpoint inhibitors; and considerations for single agent vs. combination immunotherapy.  Additionally, Dr. Postow will address the current value of immunotherapy biomarkers in patient selection and the independent and/or combined roles of immunotherapy and targeted therapy in the treatment of melanoma.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty: 
    Michael Postow, MD
    Medical Oncologist
    Memorial Sloan Kettering Cancer Center
    New York, NY

    Faculty’s disclosure
    Dr. Postow receives consulting fees from Novartis and Bristol-Myers Squibb and has contracted research with Bristol-Myers Squibb, Array BioPharma, Infinity Pharmaceuticals, Inc., and Novartis.

    Reviewers/Planners/Authors:

    • Sean T. Barrett, has nothing to disclose.
    • Colleen Braun has nothing to disclose.
    • Kia K. Gray, MPH has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Barry Mennen, MD has nothing to disclose.

    Planners and Managers

    The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose. 

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Explain the general mechanistic principles behind how immune checkpoint blockade and targeted therapy  gainst oncogenic signaling pathways differ in the treatment of metastatic melanoma.
    • Demonstrate understanding of the current landscape of immune checkpoint inhibitors and considerations for single agent use vs. combination immunotherapy in melanoma.
    • Describe the current status of immunotherapy biomarkers in melanoma, and how their value might change in the near-term.
  • Target Audience

    This activity is designed to meet the educational needs of oncologists, pharmacists, and registered nurses.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
    Postgraduate Institute for Medicine designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number – 0809-9999-16-533-HO1-P)
    Type of Activity: Knowledge
    ACPE release date: November 23, 2016

    For Pharmacists: Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service.

    Continuing Nursing Education
    The Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This educational activity for 0.4 contact hour(s) is provided by the Postgraduate Institute for Medicine.

    For Pharmacists and Nurses:
    If you wish to receive acknowledgment for completing this activity, please complete the evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 12075. Upon registering and successfully completing the activity evaluation, your certificate will be made available immediately.

  • Provider(s)/Educational Partner(s)

    Prova Education designs educational activities based on evidence-based medicine, needs and gaps analyses, learner feedback, and more. Its mission is to serve as an innovative and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education

    Co-provided by Postgraduate Institute for Medicine and Prova.

  • Commercial Support

    This activity is supported by an independent educational grant from Merck.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience."

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio
ReachMD Radio

Loading...

00:00
00:00

You must be in to display playlists.

Get a Dose of ReachMD in Your Inbox
and Practice Smarter Medicine

Stay current with the best in medical education.